Clinical trial
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed…
NCT00916409 · NovoCure Ltd., Industry · Completed
Key facts
| NCT number | NCT00916409 |
|---|---|
| Title | Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) |
| Official title | A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients With Newly Diagnosed GBM. |
| Lead sponsor | NovoCure Ltd., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Glioblastoma Multiforme |
| Intervention type | Device, Drug |
| Interventions | NovoTTF-100A device, Temozolomide |
| Enrollment | 700 |
| Start date | Jun 1, 2009 |
| Primary completion | Dec 1, 2016 |
| Completion | Mar 1, 2017 |
| First posted | Jun 9, 2009 |
| Last update posted | Apr 10, 2017 |
| Countries | Austria, Canada, Czechia, France, Germany, Israel, Italy, South Korea, Spain, Sweden, Switzerland, United States |
At a glance
- 10–99 Study sites
- No Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: